Seborrhea and Persistent Tardive Dyskinesia

References

• Barbeau A., Roy M., Gonce M., Labreoque L. Newer therapeutic approaches in Parkinson's disease. Advances in neurology, L. J. Poirier, T. L. Sourkes, P. J. Bedard. Raven Press, New York 1978; 433–437
   Google Scholar
• Burton J. L., Shuster S. Effect of L-dopa on seborrhoea of Parkinsonism. Lancet 1970; 4: 19–21
   Google Scholar
• Case T. C., Snider S. R., Hruby V. J., Rockway T. Active and inactive L-prolyl-L-leucyl glycinamide synthetic analogs in rat models of levodopa-treated Parkinson's disease. Life Schiences 1985; 36: 2531–2537
   PubMed Web of Science ®Google Scholar
• Casey D. E. Tardive dyskinesia: reversible and irreversible. Dyskinesia: research and treatment, D. E. Casey, T. N. Chase, A. V. Christensen, J. Gerlach. Springer Verlag, Berlin 1985; 88–97
   Google Scholar
• Chiu P., Rajakumar G., Chiu S., Johnson R. L., Mishra R. K. Mesolimbic and striatal dopamine receptor supersensitivity: prophlactic and reversal effects of L-prolyl-L-Leucyl-Glycinamide (PLG). Peptides 1985; 6: 179–183
   PubMed Web of Science ®Google Scholar
• Chiu S., Mishra R. K. Antagonism of morphine-induced catalepsy by L-prolyl-L-leucylglycinamide. European Journal of Pharmacology 1979; 53: 119–125
   PubMedGoogle Scholar
• Cotzias G. C., Van Woert M. H., Schiffer L. Aromatic amino acids and modifications of parkinsonism. New England Journal of Medicine 1967; 276: 374–379
   PubMed Web of Science ®Google Scholar
• Ehrensing R. H., Kastin A. J., Larsons P. F., Bishop G. A. Melanocyte-stimulating-hormone release-inhibiting factor-1 and tardive dyskinesia. Diseases of the nervous system 1977; 38: 303–307
   PubMedGoogle Scholar
• Farah I. M., Sapun M. D., Mueller G. P. Dopaminergic inhibition of pituitary beta-endorphinlike immunoreactivity secretion in the rat. Endocrinology 1982; 110: 657–659
   PubMed Web of Science ®Google Scholar
• Fischer P. A., Schneider E., Jacobi P., Maxion H. Effect of melanocyte-stimulating hormone-release inhibiting factor (MIF) in Parkinson's spndrom. European Neurology 1974; 12, 12: 360–368
   Google Scholar
• Galdi J., Rieder R. O., Silber D., Bonato R. B. Genetic factors in the response to neuroleptics in schizophrenia: A psychopahrmacological study. Psychological Medicine 1981; II: 713–728
   Google Scholar
• Gerstenbrand V. H., Binder H., Kozma S. Infusion-therapie mit MIF (melanocyte-inhibiting factor) beim Parkinson-syndrome. Wien Klinische Wochenschrift 1975; 87: 822–823
   PubMedGoogle Scholar
• Kastin A. J., Barbeau A. Preliminary clinical studies with L-prolyl-L-leucyl-glycine aminde in Parkinson's disease. Canadian Medical Association Journal 1972; 107: 1079–1081
   PubMed Web of Science ®Google Scholar
• Kastin A. J., Redding T. W., Schally A. V. MSH activity in rat pituitaries after pinealectomy. Proceedings of the Society of Experimenial Biology and Medicine 1967; 124: 1275–1277
   PubMed Web of Science ®Google Scholar
• Kastin A. J., Viosca S., Nair R. M. G., Schally A. V., Miller M. C. Interactions between pineal. hypothalamus and pituitary involving melatonin, MSH release-inhibiting factor and MSH. Endocrinology 1972; 91: 1323–1328
   PubMed Web of Science ®Google Scholar
• Kostrzewa R. M., Fukushima H., Harston C. T. Striatal dopamine turnover and MIF-I. Brain Research Bulletin 1979; 4: 799–802
   PubMedGoogle Scholar
• O'Donohue T. L., Dorsa D. M. The Opiomelanocortinergic neuronal and endocrine system. Peptides 1982; 3: 353–395
   PubMed Web of Science ®Google Scholar
• Penny R. J., Thody A. J. An improved radioimmunoassay for alpha-melanocyte-stimulating hormone (alpha-MSH) in the rat: serum and pituitary alpha-MSH levels after drugs which modify catechohminergic neurotransmission. Neuroendocrinology 1978; 25: 193–203
   PubMed Web of Science ®Google Scholar
• Pique L., Jegou S., Betagna X., Javoy-Agid F., Seurin D., Proeschel M. F., Girard F., Agid Y., Vaudry H., Luton J. P. Pro-opiomelanocortin peptides in the human hypothalamus: comparative study between normal subjects and Parkinson patients. Neuroscience Letters 1985; 54: 141–146
   PubMed Web of Science ®Google Scholar
• Rainero I., Pinessi L. Alpha-MSH and Parkinson disease. Italian journal of Niurological Sciences 1988; 9: 95–96
   PubMedGoogle Scholar
• Sandyk R., Fisher H. Increased incidence and severity of neuroleptic induced movement disorder in pinealectomized rats. International Journal of Neuroscience 1989; 48: 303–308
   PubMed Web of Science ®Google Scholar
• Shuster S., Thody A. J., Goolamali S. K., Burton J. L., Plummer N., Bates D. Melanocytestimulating hormone and Parkinsonism. Lancet 1973; I: 463–465
   Google Scholar
• Tilders F. J. H., Berkenbosch F., Smelik P. G. Control of secretion of peptides related to adrenocorticotropin. melanocyte stimulating hormone and endorphin. Frontiers of hormone research: regulation of pituitary function, T. B. Van Wimersma Greidanus. Karger, Basel 1985; 161–196
   Google Scholar
• Torre E., Celis M. E., Chiocchio S. R. Alpha-MSH and Pro-leu-gly-NH2 (PLG: MIF-1): Influence on dopamine (DA) uptake in crude synaptosomal preperations from rat mediobasal hypothalamus (MBH) and caudate putamen (CP). Peptides 1984; 5: 669–674
   PubMed Web of Science ®Google Scholar
• Versteeg D. H. G., De Crom M. P. G., Mulder A. H. ACTH-(1–24) and alphas-MSH antagonize dopamine receptor-mediated inhibition of striatal dopamine and acetylcholine release. Lefe Sciences 1986; 38: 835–840
   PubMed Web of Science ®Google Scholar